Sort
10,766 grants matching “checkpoint inhibitor”
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies
$1,253,006Amanda G Paulovich · Fred Hutchinson Cancer Center · U01 · FY2022 · CA
Innate inflammatory responses during pulmonary infections
$1,247,742Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Epigenetic Therapy for Thoracic Malignancies
$1,247,492David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2024 · CA
Natural Products Discovery and Characterization Through Network Collaborations
$1,244,726Lin Du · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Mitotic roles of the Nuclear Transport Machinery
$1,244,711Mary C. Dasso · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2015 · HD
NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER
$1,244,611New York University School Of Medicine · U01 · FY2001 · CA
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$1,242,866Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Innate inflammatory responses during pulmonary infections
$1,242,800Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$1,240,655Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy
$1,239,509Ashish Ranjan · Ut Southwestern Medical Center · R37 · FY2025 · CA
An integrated translational approach to overcome drug resistance
$1,239,225Ryan Bruce Corcoran · Massachusetts General Hospital · U54 · FY2019 · CA
Preclinical drug development in pancreatic cancer
$1,238,641Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
The Houston Center for Acquired Resistance Research (H-CARR)
$1,237,322Jeffrey Nicholas Myers · University Of Tx Md Anderson Can Ctr · U54 · FY2022 · CA
Novel SCD1 inhibitors for treatment of cancer
$1,236,819John A Copland · Modulation Therapeutics, Inc. · R42 · FY2019 · CA
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay
$1,236,637Yun Wu · State University Of New York At Buffalo · R01 · FY2025 · CA
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies
$1,236,369Brian J Druker · Oregon Health & Science University · U01 · FY2019 · CA
Development of an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer
$1,233,778Dennis Zimmermann · Matrisome Bio, Inc. · R44 · FY2025 · CA
SPORE In Prostate Cancer
$1,233,307William George Nelson · Johns Hopkins University · P50 · FY2013 · CA
Pathway inhibitors in Lymphomas
$1,231,483Mark Roschewski · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Center for Lupus Research
$1,231,434Maria Virginia Pascual · Baylor Research Institute · P50 · FY2008 · AR
The Boston Lung Cancer Survival Cohort
$1,231,212David C Christiani · Harvard School Of Public Health · U01 · FY2023 · CA
DF/HCC Kidney Cancer SPORE (supplement)
$1,230,080David McDermott · Beth Israel Deaconess Medical Center · P50 · FY2025 · CA
Cancer Prevention by Vaccination against Induced Antigens
$1,227,167Powel Brown · University Of Tx Md Anderson Can Ctr · N01 · FY2019 · CA
Pediatric Oncology Branch Behavioral Science Core
$1,225,916John Glod · Division Of Basic Sciences - Nci · ZID · FY2022 · CA
An integrated translational approach to overcome drug resistance
$1,224,938Ryan Bruce Corcoran · Massachusetts General Hospital · U54 · FY2021 · CA